Monoclonal Antibody Against Tissue Factor Shortens Tissue Plasminogen Activator Lysis Time and Prevents Reocclusion in a Rabbit Model of Carotid Artery Thrombosis
- 15 May 1996
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 93 (10) , 1913-1918
- https://doi.org/10.1161/01.cir.93.10.1913
Abstract
Background Tissue factor (TF)–dependent activation of the coagulation is important in the pathophysiology of intravascular thrombus formation. We tested the effects of a monoclonal antibody against TF (AP-1) on lysis time induced by tissue-type plasminogen activator (TPA) and on reocclusion rate in a rabbit model of carotid artery thrombosis. Methods and Results Intravascular thrombosis was obtained by placing an external constrictor around carotid arteries with endothelial injury. Carotid blood flow velocity was measured continuously with a Doppler flow probe. Thirty minutes after thrombus formation, the rabbits received either AP-1 (0.15 mg/kg IV, n=8) or placebo (n=8). All rabbits also received TPA (80 μg/kg bolus plus 8 μg·kg −1 ·min −1 infusion for up to 90 minutes or until reperfusion was achieved) and heparin (200 U/kg IV as a bolus). At reperfusion, TPA was discontinued, and the rabbits were followed for an additional 90 minutes. AP-1 shortened lysis time from 44±8 minutes (mean±SEM) in control rabbits to 26±7 minutes in AP-1–treated rabbits ( P <.01). Reocclusion occurred in all control rabbits in 10±3 minutes, whereas it occurred in only two of eight AP-1–treated rabbits in 72 and 55 minutes ( P <.01). No changes in prothrombin time and ex vivo platelet aggregation in response to various agonists were observed after AP-1 administration, indicating the absence of systemic effects by this antibody. Conclusions TF exposure and activation of the extrinsic coagulation pathway play an important role in prolonging lysis time and mediating reocclusion after thrombolysis in this model. AP-1, a monoclonal antibody against TF, might be suitable as adjunctive therapy to TPA.Keywords
This publication has 11 references indexed in Scilit:
- A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trialJournal of the American College of Cardiology, 1994
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Atherosclerosis: what is it and why does it occur?Heart, 1993
- Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activatorJournal of the American College of Cardiology, 1992
- Thrombin structure and functionBlood Coagulation & Fibrinolysis, 1991
- Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.Journal of Clinical Investigation, 1990
- Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysisJournal of the American College of Cardiology, 1987
- Iliac artery mural thrombus formation. Effect of antiplatelet therapy on 111In-platelet deposition in baboons.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- RENAL, HAEMODYNAMIC, AND HORMONAL EFFECTS OF HUMAN ALPHA ATRIAL NATRIURETIC PEPTIDE IN HEALTHY VOLUNTEERSThe Lancet, 1985